LENSAR stock: Recurring revenue rises 17% in Q3
Published on 11/19/2026 at 03:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRecurring revenue strengthens the mix
- Recurring revenue rose 17% year over year to 12.6 million US dollars and accounted for 89% of quarterly revenue.
- Procedure volume increased 12% to 52,545, while the ALLY installed base reached approximately 225 systems.
- Adjusted EBITDA improved to 1.7 million US dollars, although the GAAP net loss widened to 4.7 million US dollars.
LENSAR reported mixed third-quarter results on November 10, 2026, with stronger recurring revenue and procedure activity offsetting lower system sales. The cataract-technology company said revenue for the quarter ended September 30 declined 1% year over year to 14.131 million US dollars. The company release attributed the pressure primarily to lower system sales against a strong year-earlier comparison.
Recurring sales support the quarter
Recurring revenue increased 17% to 12.584 million US dollars from 10.770 million US dollars a year earlier and represented 89% of total revenue, compared with 75% in the prior-year quarter. Procedure revenue rose 17% to 9.168 million US dollars, while procedure volume climbed 12% to 52,545 procedures from 46,811.
LENSAR placed 10 ALLY systems during the quarter, taking the installed ALLY base to approximately 225 systems. The total laser installed base reached approximately 450 systems, and 12 ALLY systems were awaiting installation at September 30.
Loss widens despite operating improvement
The operating loss narrowed to 1.433 million US dollars from 7.580 million US dollars a year earlier. Adjusted EBITDA improved to 1.669 million US dollars from a loss of 0.298 million US dollars, but the GAAP net loss widened to 4.723 million US dollars from 3.713 million US dollars.
The reported net loss included a 3.365 million US dollar expense from changes in the fair value of warrant liabilities. Cash, cash equivalents and investments totaled 12.6 million US dollars at September 30, compared with 18.0 million US dollars at December 31, 2025.
Robotic cataract systems remain central
LENSAR designs, develops and markets robotic laser systems for cataract treatment and astigmatism management. Its ALLY system combines a dual-modality laser with imaging and software, and is intended for use in operating rooms or office-based surgical suites. The company is based in the United States and sells through direct and distributor channels in its medical-device markets.
LENSAR quarterly snapshot
- Company: LENSAR, Inc.
- Ticker: LNSR
- Home exchange: Nasdaq
- Reporting period: Quarter ended September 30, 2026
- Revenue: 14.131 million US dollars
- Recurring revenue: 12.584 million US dollars
- Procedure volume: 52,545
- Adjusted EBITDA: 1.669 million US dollars
- GAAP net loss: 4.723 million US dollars
LENSAR operates within the U.S. equity market tracked by the S&P 500.
More news and analyses on LENSAR stock are available here.
